文献速递基础与转化研究新药、器械与细胞基因治疗研发

靶向嘧啶合成增强胶质母细胞瘤干细胞的分子治疗反应

Targeting pyrimidine synthesis accentuates molecular therapy response in glioblastoma stem cells.
PubMed 文献 · Sci Transl Med · 2019-01-01

该研究在啮齿类模型中追踪胶质母细胞瘤干细胞(GSC)的代谢异常,将其与胶质母细胞瘤核心基因突变及对新发嘧啶合成的依赖联系起来;靶向CAD或DHODH可抑制GSC存活、自我更新和体内成瘤;EGFR或PTEN突变产生不同CAD磷酸化模式以激活嘧啶合成碳流入;联合临床已批准抑制剂可持续抑制嘧啶合成代谢活性与GSC致瘤能力(体外);嘧啶合成基因高表达提示患者预后不良。

要点

  • 靶向嘧啶合成限速酶CAD或下游关键酶DHODH可抑制GSC存活、自我更新和体内成瘤。
  • EGFR或PTEN突变产生不同CAD磷酸化模式,激活嘧啶合成碳流入。
  • 临床已批准抑制剂同时阻断肿瘤特异性驱动突变与DHODH活性,体外持续抑制嘧啶合成代谢活性和GSC致瘤能力。

核心结论

  • 结果证明靶向驱动突变与癌症干细胞代谢重编程之间联系的可实现精准医学治疗途径。

研究设计与样本

  • 研究在啮齿类模型中追踪GSC代谢异常,将胶质母细胞瘤核心基因突变与对新发嘧啶合成的依赖相联系。

主要发现

  • 靶向CAD或DHODH通过耗竭嘧啶核苷酸供应抑制GSC存活、自我更新和体内肿瘤起始。
  • EGFR或PTEN突变产生不同CAD磷酸化模式以激活嘧啶合成碳流入。
  • 临床已批准抑制剂同时阻断肿瘤特异性驱动突变与DHODH活性,在体外持续抑制嘧啶合成代谢活性和GSC致瘤能力。
  • 嘧啶合成基因高表达提示胶质母细胞瘤患者预后不良。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Glioblastoma stem cells (GSCs) reprogram glucose metabolism by hijacking high-affinity glucose uptake to survive in a nutritionally dynamic microenvironment. Here, we trace metabolic aberrations in GSCs to link core genetic mutations in glioblastoma to dependency on de novo pyrimidine synthesis. Targeting the pyrimidine synthetic rate-limiting step enzyme carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, dihydroorotase (CAD) or the critical downstream enzyme dihydroorotate dehydrogenase (DHODH) inhibited GSC survival, self-renewal, and in vivo tumor initiation through the depletion of the pyrimidine nucleotide supply in rodent models. Mutations in EGFR or PTEN generated distinct CAD phosphorylation patterns to activate carbon influx through pyrimidine synthesis. Simultaneous abrogation of tumor-specific driver mutations and DHODH activity with clinically approved inhibitors demonstrated sustained inhibition of metabolic activity of pyrimidine synthesis and GSC tumorigenic capacity in vitro. Higher expression of pyrimidine synthesis genes portends poor prognosis of patients with glioblastoma. Collectively, our results demonstrate a therapeutic approach of precision medicine through targeting the nexus between driver mutations and metabolic reprogramming in cancer stem cells.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Wang X, Yang K, Wu Q, et al. Targeting pyrimidine synthesis accentuates molecular therapy response in glioblastoma stem cells. Sci Transl Med. 2019. PMID: 31391321. doi:10.1126/scitranslmed.aau4972

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。